Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Prof Nicolas Girard - Institut Curie, Paris, France
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )
7 Apr 2025

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands
Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )
7 Apr 2025

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Subcutaneous pembrolizumab is a viable treatment option for mNSCLC ( Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
7 Apr 2025

SIOG 2024: Updates in radiation oncology

Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia
SIOG 2024: Updates in radiation oncology ( Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia )
19 Feb 2025

SIOG 2024: Updates in medical oncology

Dr Capucine Baldini - Gustave Roussy, Villejuif, France
SIOG 2024: Updates in medical oncology ( Dr Capucine Baldini - Gustave Roussy, Villejuif, France )
19 Feb 2025

Ageing and cancer: Inflammation promotes ageing-associated oncogenesis in the lung

Dr James DeGregori - University of Colorado School of Medicine, Aurora, Colorado
Ageing and cancer: Inflammation promotes ageing-associated oncogenesis in the lung ( Dr James DeGregori - University of Colorado School of Medicine, Aurora, Colorado )
17 Feb 2025

Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study

Dr Camille Chakiba - Institute Bergonié, Bordeaux, France
Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study ( Dr Camille Chakiba - Institute Bergonié, Bordeaux, France )
1 Nov 2024

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India
WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )
23 Oct 2024

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )
23 Oct 2024

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation

Dr Rom Leidner - Providence Cancer Institute, Portland, USA
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )
17 Oct 2024

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )
9 Oct 2024